Smith+Nephew Completes First Clinical Cases with CORI XT Surgical Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: Newsfilter
- Surgical Platform Innovation: Smith+Nephew's CORI XT handheld robotic platform successfully completed its first shoulder arthroplasty at Duke Health, marking the platform's debut in shoulder surgeries and showcasing its potential and technological advantages in surgical applications.
- Versatile Applications: The CORI XT platform not only excelled in shoulder arthroplasty but also completed its first knee replacement at NYU Langone Health, further proving its adaptability and flexibility across different surgical environments.
- Enhanced Surgical Efficiency: Designed to improve surgical precision while maintaining workflow efficiency, the platform allows surgeons to operate without altering existing procedures, thereby enhancing operational flow and patient recovery potential.
- Strategic Market Expansion: Through the clinical application of the CORI XT platform, Smith+Nephew demonstrates its innovative capabilities in medical technology, which is expected to drive further growth in the global orthopedic market and strengthen its competitive position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNN
Wall Street analysts forecast SNN stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 30.500
Low
34.00
Averages
35.75
High
37.50
Current: 30.500
Low
34.00
Averages
35.75
High
37.50
About SNN
Smith & Nephew plc is a portfolio medical technology company. The Company is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The Company also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Conexeu Sciences Expands Board to Support Commercialization Efforts
- Board Expansion: On June 15, 2026, Conexeu Sciences Inc. expanded its board from six to nine members, with new directors primarily from Fortune 500 companies, signaling the company's ambition to transition its cutting-edge tissue regeneration technology into a viable business.
- Executive Appointment: Co-founder David Bogart was promoted to Chief Commercial Officer, overseeing over $75 million in capital formation, indicating Conexeu's focus on commercial strategy and market outreach to lay the groundwork for future growth.
- Technology Platform: Conexeu's CXU™ platform is a bioregenerative extracellular matrix that rapidly transitions into a stable gel scaffold at body temperature, expected to target multiple billion-dollar markets including advanced wound care and medical aesthetics, showcasing its broad market potential.
- Market Outlook: With an aging population and the diabetes epidemic, the field of tissue regeneration is experiencing strong market momentum, and while Conexeu faces challenges from larger competitors, its unique technology and leadership team position it well for future success.
See More
Smith+Nephew Completes First Clinical Cases with CORI XT Surgical Platform
- Surgical Platform Innovation: Smith+Nephew's CORI XT handheld robotic platform successfully completed its first shoulder arthroplasty at Duke Health, marking the platform's debut in shoulder surgeries and showcasing its potential and technological advantages in surgical applications.
- Versatile Applications: The CORI XT platform not only excelled in shoulder arthroplasty but also completed its first knee replacement at NYU Langone Health, further proving its adaptability and flexibility across different surgical environments.
- Enhanced Surgical Efficiency: Designed to improve surgical precision while maintaining workflow efficiency, the platform allows surgeons to operate without altering existing procedures, thereby enhancing operational flow and patient recovery potential.
- Strategic Market Expansion: Through the clinical application of the CORI XT platform, Smith+Nephew demonstrates its innovative capabilities in medical technology, which is expected to drive further growth in the global orthopedic market and strengthen its competitive position.
See More
Smith+Nephew Launches Next-Gen LEAF Patient Monitoring System in the US
- Market Demand Response: Smith+Nephew's LEAF Patient Monitoring System addresses the approximately 60,000 annual deaths in the US attributed to hospital-acquired pressure injuries (HAPIs), potentially significantly reducing the economic burden of up to $26.8 billion annually on healthcare systems.
- Technological Innovation: The system utilizes a wearable sensor to monitor patient mobility in real-time, enhancing workflow efficiency and protocol adherence, thereby ensuring timely care for patients amidst staffing shortages and workload pressures.
- User Experience Optimization: The cloud-hosted LEAF system, designed in consultation with multidisciplinary nursing teams, features an intuitive user interface and document automation, enabling nurses to quickly access critical information and streamline patient management processes.
- Significant Economic Benefits: The LEAF system monitors over 150,000 patients annually in a critical care facility, reducing the odds of HAPIs by up to 73% and delivering estimated savings of up to $1.8 million, highlighting its critical value in the healthcare industry.
See More
Surge of Regenerative Medicine IPOs
- New Company Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with over 25.2 million shares issued, as CEO emphasized their CXU™ platform's goal to rebuild biological structures, potentially attracting significant investor interest in regenerative medicine.
- Significant Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025, with gross margins at a historic high of 79.4%, reflecting strong demand for its non-opioid pain therapies, which may lead to increased capital inflows into related companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and equivalents with no debt in Q1 2026, and its TrueDent® resins received CE marking, enhancing its penetration in the European market and strengthening the bioprinting industry's infrastructure.
- Wound Care Innovation: Smith & Nephew launched ALLEVYN COMPLETE CARE Foam Dressing in the U.S. in March 2026, targeting chronic wound management with robust scientific backing, addressing the growing global demand for wound care and further expanding the regenerative medicine market.
See More
Surge of Regenerative Medicine IPOs
- New Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with 25,269,996 shares issued, as CEO emphasized the CXU™ platform's goal to rebuild biological architecture, targeting over 100,000 women annually for breast reconstruction.
- Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025 with a GAAP gross margin of 79.4%, reflecting strong market demand for non-opioid pain therapies, which is driving capital back into early-stage regenerative medicine companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and short-term deposits with no debt in Q1 2026, and its TrueDent® resins received CE marking, marking a significant advancement in its bioprinting technology in the European market.
- Wound Care Innovation: Smith & Nephew launched the ALLEVYN COMPLETE CARE Foam Dressing in the U.S. on March 10, 2026, addressing the global demand for advanced wound care products, further propelling the commercialization of regenerative medicine.
See More
Smith & Nephew Announces $250 Million Share Buyback Agreement
- Buyback Program Initiation: Smith & Nephew has entered into an agreement with Merrill Lynch International to repurchase up to $250 million of shares at $0.20 per share, aimed at reducing the company's issued share capital, thereby enhancing earnings per share and shareholder value.
- Repurchase Timeline: The first tranche of the buyback will commence on May 8 and conclude no later than September 7, providing the company with flexibility to adapt to market conditions and optimize its capital structure.
- Capital Structure Optimization: By reducing the number of issued shares, Smith & Nephew aims to boost market demand for its stock, potentially enhancing share price performance, which reflects the company's confidence in future growth and commitment to shareholders.
- Merrill Lynch's Role: Merrill Lynch International will execute the share buyback, ensuring smooth transactions while providing Smith & Nephew with professional market support, further solidifying its market position in the medical technology sector.
See More
Conexeu Sciences Expands Board to Support Commercialization Efforts
- Board Expansion: On June 15, 2026, Conexeu Sciences Inc. expanded its board from six to nine members, with new directors primarily from Fortune 500 companies, signaling the company's ambition to transition its cutting-edge tissue regeneration technology into a viable business.
- Executive Appointment: Co-founder David Bogart was promoted to Chief Commercial Officer, overseeing over $75 million in capital formation, indicating Conexeu's focus on commercial strategy and market outreach to lay the groundwork for future growth.
- Technology Platform: Conexeu's CXU™ platform is a bioregenerative extracellular matrix that rapidly transitions into a stable gel scaffold at body temperature, expected to target multiple billion-dollar markets including advanced wound care and medical aesthetics, showcasing its broad market potential.
- Market Outlook: With an aging population and the diabetes epidemic, the field of tissue regeneration is experiencing strong market momentum, and while Conexeu faces challenges from larger competitors, its unique technology and leadership team position it well for future success.
See More
Smith+Nephew Completes First Clinical Cases with CORI XT Surgical Platform
- Surgical Platform Innovation: Smith+Nephew's CORI XT handheld robotic platform successfully completed its first shoulder arthroplasty at Duke Health, marking the platform's debut in shoulder surgeries and showcasing its potential and technological advantages in surgical applications.
- Versatile Applications: The CORI XT platform not only excelled in shoulder arthroplasty but also completed its first knee replacement at NYU Langone Health, further proving its adaptability and flexibility across different surgical environments.
- Enhanced Surgical Efficiency: Designed to improve surgical precision while maintaining workflow efficiency, the platform allows surgeons to operate without altering existing procedures, thereby enhancing operational flow and patient recovery potential.
- Strategic Market Expansion: Through the clinical application of the CORI XT platform, Smith+Nephew demonstrates its innovative capabilities in medical technology, which is expected to drive further growth in the global orthopedic market and strengthen its competitive position.
See More
Smith+Nephew Launches Next-Gen LEAF Patient Monitoring System in the US
- Market Demand Response: Smith+Nephew's LEAF Patient Monitoring System addresses the approximately 60,000 annual deaths in the US attributed to hospital-acquired pressure injuries (HAPIs), potentially significantly reducing the economic burden of up to $26.8 billion annually on healthcare systems.
- Technological Innovation: The system utilizes a wearable sensor to monitor patient mobility in real-time, enhancing workflow efficiency and protocol adherence, thereby ensuring timely care for patients amidst staffing shortages and workload pressures.
- User Experience Optimization: The cloud-hosted LEAF system, designed in consultation with multidisciplinary nursing teams, features an intuitive user interface and document automation, enabling nurses to quickly access critical information and streamline patient management processes.
- Significant Economic Benefits: The LEAF system monitors over 150,000 patients annually in a critical care facility, reducing the odds of HAPIs by up to 73% and delivering estimated savings of up to $1.8 million, highlighting its critical value in the healthcare industry.
See More
Surge of Regenerative Medicine IPOs
- New Company Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with over 25.2 million shares issued, as CEO emphasized their CXU™ platform's goal to rebuild biological structures, potentially attracting significant investor interest in regenerative medicine.
- Significant Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025, with gross margins at a historic high of 79.4%, reflecting strong demand for its non-opioid pain therapies, which may lead to increased capital inflows into related companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and equivalents with no debt in Q1 2026, and its TrueDent® resins received CE marking, enhancing its penetration in the European market and strengthening the bioprinting industry's infrastructure.
- Wound Care Innovation: Smith & Nephew launched ALLEVYN COMPLETE CARE Foam Dressing in the U.S. in March 2026, targeting chronic wound management with robust scientific backing, addressing the growing global demand for wound care and further expanding the regenerative medicine market.
See More
Surge of Regenerative Medicine IPOs
- New Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with 25,269,996 shares issued, as CEO emphasized the CXU™ platform's goal to rebuild biological architecture, targeting over 100,000 women annually for breast reconstruction.
- Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025 with a GAAP gross margin of 79.4%, reflecting strong market demand for non-opioid pain therapies, which is driving capital back into early-stage regenerative medicine companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and short-term deposits with no debt in Q1 2026, and its TrueDent® resins received CE marking, marking a significant advancement in its bioprinting technology in the European market.
- Wound Care Innovation: Smith & Nephew launched the ALLEVYN COMPLETE CARE Foam Dressing in the U.S. on March 10, 2026, addressing the global demand for advanced wound care products, further propelling the commercialization of regenerative medicine.
See More
Smith & Nephew Announces $250 Million Share Buyback Agreement
- Buyback Program Initiation: Smith & Nephew has entered into an agreement with Merrill Lynch International to repurchase up to $250 million of shares at $0.20 per share, aimed at reducing the company's issued share capital, thereby enhancing earnings per share and shareholder value.
- Repurchase Timeline: The first tranche of the buyback will commence on May 8 and conclude no later than September 7, providing the company with flexibility to adapt to market conditions and optimize its capital structure.
- Capital Structure Optimization: By reducing the number of issued shares, Smith & Nephew aims to boost market demand for its stock, potentially enhancing share price performance, which reflects the company's confidence in future growth and commitment to shareholders.
- Merrill Lynch's Role: Merrill Lynch International will execute the share buyback, ensuring smooth transactions while providing Smith & Nephew with professional market support, further solidifying its market position in the medical technology sector.
See More
